NCATS develops novel approaches to improve the process of joining basic science discoveries with initial testing of therapies in humans.
-
Research
-
Preclinical Innovation
NCATS Seeks Applications to Repurpose Existing Drugs to Advance COVID-19 Research
NCATS issued a Notice of Special Interest that highlights the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19) through repurposing existing drugs.
Reprogramming Immune Cells to Fight Tumors
Immunotherapy holds immense power in harnessing the body’s immune system to fight diseases. Researchers have shown a novel type of immune therapy can reprogram immune cells to stop tumor growth and kill cancer cells.
A Multipronged Approach Toward Treating DMD
Scientists discover a one-for-all approach toward lessening the symptoms of Duchenne muscular dystrophy and neurodegenerative diseases using high-throughput screening and a mouse model.
Improving the Drug Development ProcessCreating and testing innovative methods to improve and accelerate the drug development process and find new treatments for patients faster.
Repurposing DrugsDiscovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
Testing & Predictive ModelsDeveloping better model systems for drug and toxicity testing.
Core TechnologiesUsing state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Improving the Drug Development Process
Creating and testing innovative methods to improve and accelerate the drug development process and find new treatments for patients faster.
Discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
Developing better model systems for drug and toxicity testing.
Using state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Work with Us
NCATS preclinical programs and resources focus on key obstacles and inefficiencies in the translational process, overcoming bottlenecks that slow the development of new treatments for patients.
Learn more about how to access NCATS programs and expertise.
Inside the NCATS Laboratories
Take a video tour of our labs and see firsthand how our researchers work to get more treatments to more patients more quickly.
Learn more about NCATS’ Achievements in Advancing Translational Sciences.
NCATS Programs & Resources Supporting Preclinical Innovation
- 3-D Tissue Bioprinting Program
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses)
- Extracellular RNA Communication
- Matrix Combination Screening
- NCATS Chemical Genomics Center (NCGC)
- NCATS Pharmaceutical Collection
- Pfizer's Centers for Therapeutic Innovation (CTI) for NIH Researchers
- RNA Interference (RNAi)
- Therapeutics for Rare and Neglected Diseases (TRND)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
-
